Gedeon Richter Plc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gedeon Richter Plc.
Myovant, Bayer and Rhythm Pharmaceuticals are among the companies that could soon learn whether the European Medicines Agency thinks their drugs are fit for approval.
Eden Biologics adds Henlius’ Scott Liu to its board of directors, as both King & Spalding and Gedeon Richter also make fresh appointments. And Stada has extended the tenure of CEO Peter Goldschmidt.
New treatments for congenital adrenal hyperplasia and relapsing forms of multiple sclerosis are among five drugs recommended for pan-EU approval this month. In addition, harmonized EU advice has been issued for Celltrion’s monoclonal antibody COVID-19 treatment.
An new $2.1bn incentive scheme for formulations follows on from an earlier scheme for APIs in India. Experts weigh in on the likelihood of industry participation and whether this $3bn push will result in $41bn of incremental sales for the industry while strengthening supply chains in a post-COVID world.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- PregLem Holding SA
- Richter Gedeon Vegyeszeti Gyar Nyrt
- Richter-Helm BioTec GmbH
- FINOX Biotech
- Finox AG